

Accepted Manuscript

Commentary

Pharmacological Inhibition of Cathepsin K: a Promising Novel Approach for Postmenopausal Osteoporosis Therapy

Kakoli Mukherjee, Naibedya Chattopadhyay

PII: S0006-2952(16)30049-1
DOI: <http://dx.doi.org/10.1016/j.bcp.2016.04.010>
Reference: BCP 12536

To appear in: *Biochemical Pharmacology*

Received Date: 30 December 2015
Accepted Date: 12 April 2016

Please cite this article as: K. Mukherjee, N. Chattopadhyay, Pharmacological Inhibition of Cathepsin K: a Promising Novel Approach for Postmenopausal Osteoporosis Therapy, *Biochemical Pharmacology* (2016), doi: <http://dx.doi.org/10.1016/j.bcp.2016.04.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Pharmacological Inhibition of Cathepsin K: a Promising Novel Approach for Postmenopausal Osteoporosis Therapy

Kakoli Mukherjee^{1, 2} and Naibedya Chattopadhyay³

¹Alkem Laboratories Ltd, NCE R&D, Bangalore, India; ²Integral Biosciences, Biology Department, C64-Hosiery Complex, Phase II extension, Noida-201306, India; ³Division of Endocrinology and Center for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Sector 10 Jankipuram Extension, Sitapur Road, Lucknow 226031, India

Running title: Cathepsin K inhibitors as therapy for osteoporosis

Supporting grants: Council of Scientific and Industrial Research, Government of India.

***Correspondence:** Naibedya Chattopadhyay; Tel: +91-522 2613894; Fax: +91-522 2623938; Email: n_chattopadhyay@cdri.res.in or Kakoli Mukherjee; Tel:+91-120-466322; Fax: +91-120-4663223; Email: kakoli.mukherjee@ibs.net.in

Disclosures: NC has received a) consultancy fees from Glenmark Pharmaceuticals, Navi Mumbai, India, b) consultancy fees and research support from GlaxoSmithKline-Consumer Healthcare, Gurgaon, India, and c) been an Scientific Advisory Board Member of Alkem Laboratories Ltd, India. KM has nothing to declare.

Abbreviations:

Cathepsin K: CatK; Odanacatib: ODN; bone mineral density: BMD; dual X-ray absorptiometry: DXA; Receptor activator of nuclear factor kappaB ligand: RANKL; osteoporosis: OP; osteoarthritis: OA; metastatic bone disease: MBD; p-dihydroxanthone: DHT; collagen type 1 cross-linked C-telopeptide: CTx/CTX; N-terminal telopeptide: NTx/NTX; bone mineral density: BMD; bone mineral content: BMC; Bone formation rate: BFR; Tartarate resistant acid phosphatase: TRAP; quantitative computed tomography: QCT;

Download English Version:

<https://daneshyari.com/en/article/5552399>

Download Persian Version:

<https://daneshyari.com/article/5552399>

[Daneshyari.com](https://daneshyari.com)